BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31228134)

  • 1. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
    Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
    van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
    Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
    Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.
    Kantor O; Wakeman M; Weiss A; Wong S; Laws A; Grossmith S; Mittendorf EA; King TA
    Ann Surg Oncol; 2021 Mar; 28(3):1358-1367. PubMed ID: 32869154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
    Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
    J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
    [No Abstract]   [Full Text] [Related]  

  • 7. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.
    Wong SM; Weiss A; Mittendorf EA; King TA; Golshan M
    Ann Surg Oncol; 2019 Oct; 26(11):3517-3525. PubMed ID: 31342389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis.
    Fayanju OM; Ren Y; Suneja G; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Force J; Hyslop T; Hwang ES
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):377-389. PubMed ID: 31678225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
    Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
    Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
    Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
    Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Breast Cancer Res Treat; 2018 Sep; 171(2):359-369. PubMed ID: 29846847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
    Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
    Sutton TL; Schlitt A; Gardiner SK; Johnson N; Garreau JR
    J Surg Oncol; 2020 Dec; 122(8):1761-1769. PubMed ID: 33125715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.
    Zhang GC; Zhang YF; Xu FP; Qian XK; Guo ZB; Ren CY; Yao M
    Curr Oncol; 2013 Jun; 20(3):e180-92. PubMed ID: 23737688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
    Weiss A; Campbell J; Ballman KV; Sikov WM; Carey LA; Hwang ES; Poppe MM; Partridge AH; Ollila DW; Golshan M
    Ann Surg Oncol; 2021 Oct; 28(11):5960-5971. PubMed ID: 33821344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Huang Z; Zhu L; Huang XB; Tang Y; Rong QL; Shi M; Wang WH; Tie J; Shen LF; Chen JY; Zhang J; Wu HF; Cheng J; Liu M; Tan YT; Ma CY; Wang SL; Li YX
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1030-1039. PubMed ID: 32585337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.